The present invention relates to novel compounds that inhibit Lp-PLA 2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA 2 , for example atherosclerosis, Alzheimer's disease.
1. A compound which is
or a salt thereof.
2. A compound which is
or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 1 which is (R)-3-((3, 5-difluoro-4-((2-(trifluoromethyl) pyridin-4-yl) oxy) benzyl) oxy)-7, 8, 8a, 9-tetra hydropyrrolo[1′,2′:3 ,4]imidazo [1,2-c]pyrimidin-1(6H)-one
or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 1 which is (R)-3-((3, 5-difluoro-4-((2-(trifluoromethyl) pyridin-4-yl) oxy) benzyl) oxy)-7, 8, 8a, 9-tetra hydropyrrolo[1′,2′:3,4]imidazo[1,2-c]pyrimidin-1(6H)-one
5. The compound according to claim 1 which is a pharmaceutically acceptable salt of (R)-3-((3, 5-difluoro-4-((2-(trifluoromethyl) pyridin-4-yl) oxy) benzyl) oxy)-7, 8, 8a, 9-tetra hydropyrrolo[1′,2′:3,4]imidazo[1,2-c]pynmidin-1(6H)-one
6. The compound according to claim 1 which is (S)-3-((3, 5-difluoro-4-((2-(trifluoromethyl) pyridin-4-yl) oxy) benzyl) oxy)-7, 8, 8a, 9-tetra hydropyrrolo[1′,2′:3 ,4]imidazo[1,2-c]pyrimidin-1(6H)-one
or a pharmaceutically acceptable salt thereof.
7. The compound according to claim 1 , which is (S)-3-((3, 5-difluoro-4-((2-(trifluoromethyl) pyridm-4-yl) oxy) benzyl) oxy)-7, 8, 8a, 9-tetra hydropyrrolo[1′,2′:3 ,4]imidazo[1,2-c]pyrimidin-1(6H)-one
8. The compound according to claim 1 , which is a pharmaceutically acceptable salt of (S)-3-((3, 5-difluoro-4-((2-(trifluoromethyl) pyridm-4-yl) oxy) benzyl) oxy)-7, 8, 8a, 9-tetra hydropyrrolo[1′,2′:3,4]imidazo[1,2-c]pyrimidin-1(6H)-one
9. A pharmaceutical composition comprising a compound having a structure of
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
10. The pharmaceutical composition according to claim 9 wherein the compound has the structure of
or a pharmaceutically acceptable salt thereof.
11. The pharmaceutical composition according to claim 9 wherein the compound has the structure of
or a pharmaceutically acceptable salt thereof.
12. A method for treating neurodegeneration disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound having a structure of
or a pharmaceutically acceptable salt thereof.
13. The method according to claim 12 , wherein the neurodegeneration disease is Alzheimer's disease.
14. The method according to claim 12 , wherein the compound has the structure of
or a pharmaceutically acceptable salt thereof.
15. The method according to claim 12 , wherein the compound has the structure of
or a pharmaceutically acceptable salt thereof.
16. The method according to claim 12 , wherein the subject is human.